Sexual Health in Aging — Body Handbook

Healthcare · §659

Sexual Health in Aging

What you've been quietly putting down to age is, in most cases, a thing with a fix — often a cheap one. The performance trouble in your fifties, the dryness in your sixties, the libido the antidepressant took: each has a treatment a clinician could write in fifteen minutes if you raised it. And in men, the trouble itself is a window onto the heart attack arriving five years from now — caught early enough to bend its course. The bedroom doesn't have to go quiet for the rest of the body to stay loud.

Do · Daily Evidence Moderate Chapter Healthcare

Three moves. Raise the bedroom problems with a clinician once — every category here has cheap, evidence-backed treatment, including the ones nobody mentions to you. Treat erection trouble as a heart warning, not a sex problem. And use condoms with new partners: the fastest-rising sexually-transmitted-infection demographic in the US is now adults over fifty-five.

Three things drive most of it. Blood vessels. The arteries that supply an erection are one to two millimeters across; the ones supplying the heart are three to four; the carotids are five to seven. Atherosclerosis — the slow narrowing of artery walls that ends in heart attacks and strokes — declares itself in the smallest vessels first. A man whose erection trouble shows up in his fifties is, statistically, three to five years in front of a vascular event waiting to happen in his coronaries Vlachopoulos et al. 2013. The same is true downstream of diabetes, high blood pressure, and smoking — all of them damage the same vessels.

Hormones. In women, the menopausal estrogen drop thins vaginal tissue, raises its pH, and reduces lubrication. Unlike hot flashes, which fade over years on their own, this vulvovaginal change — a clinician calls it genitourinary syndrome of menopause — keeps getting worse without treatment Portman and Gass 2014. In men, testosterone falls about one percent a year after thirty or forty — but the dramatic low T stories you've seen marketed are not what most aging men have. Strict criteria identify symptomatic deficiency in only about two percent of men forty to seventy-nine Wu et al. 2010. Most low total testosterone in a middle-aged man is actually symptomatic of something else — abdominal weight, untreated sleep apnea, depression — and reverses when that something else is treated.

Other people's drugs. The pills you take for things that have nothing to do with sex routinely flatten it. The serotonin-class antidepressants — the SSRIs, the family most commonly prescribed for depression and anxiety — cause sexual side effects in fifty-eight to seventy-three percent of patients when somebody asks, far higher than the rate that gets volunteered Montejo et al. 2001. Older beta blockers (propranolol, atenolol) lower erection rates. Finasteride, prescribed for hair loss or prostate growth, causes low libido and erectile trouble in a meaningful minority. Long-term opioids suppress testosterone. None of this is age — it is the medicine cabinet.

The single biggest thing erection trouble is telling you

The penis is a stress test you didn't book. Picture the arteries in your body as pipes of decreasing diameter — the legs, the carotids, the coronaries that feed your heart, and at the bottom of the size ladder, the cavernosal arteries that fill the penis. When the inside of those pipes starts to roughen and narrow, the smallest go first. By the time a coronary is narrow enough to give you angina, the penile artery has been failing for years.

The practical consequence: a man under seventy whose erections change should get a cardiovascular workup before he gets a sildenafil prescription. Blood pressure, cholesterol, fasting glucose, an honest conversation about smoking and weight. The bedroom trouble is the symptom; the heart attack is the disease. Treat the disease.

The connection runs both ways. Esposito's two-year trial in obese men with erectile dysfunction: a Mediterranean-pattern diet plus regular exercise restored normal function in about one in three intervention-arm men, alongside measurable improvement in the blood-vessel-lining markers — the same intervention that bends cardiovascular risk also bends what happens in bed Esposito et al. 2004. The Health Professionals Follow-up cohort tracked roughly thirty-one thousand men over fourteen years: physical activity, normal weight, not smoking, and moderate alcohol each independently predicted preserved sexual function into the seventies Bacon et al. 2003.

And the broader signal that does not run through any single artery: across one hundred and forty-eight studies and three hundred thousand people, having strong intimate relationships was associated with roughly 50% higher odds of survival over the follow-up period — comparable to quitting smoking, bigger than not being obese Holt-Lunstad et al. 2010. The bedroom is not the whole partnership, but in long marriages it is part of the load-bearing structure.

What to actually do

The catalogue of fixes is broad and almost none of it is new. The barrier is conversational — you have to raise it. A national study of older adults found that only thirty-eight percent of men and twenty-two percent of women had ever discussed sex with a clinician since age fifty Lindau et al. 2007. Bring it up at the next check-up and most of the rest of this entry takes care of itself.

Before you treat anything, audit the pills you're already on

The medicine cabinet causes a lot of this. Antidepressants in the SSRI class are the single biggest iatrogenic source — switching to bupropion or mirtazapine resolves a meaningful share of cases. Older beta blockers can be swapped for carvedilol or nebivolol, both of which have lower sexual side-effect rates. Finasteride for hair loss is a real conversation, not an automatic yes. None of these are decisions to make on your own, but they are conversations to start before you accept a second prescription on top of the first.

If you are a man

Sildenafil, tadalafil, and the rest of the family restore successful intercourse from about a quarter to roughly two-thirds in trials, across most underlying causes including diabetes and the aftermath of prostate surgery Goldstein et al. 1998. Generic sildenafil is now pennies a dose; tadalafil's low daily dose removes the timing problem altogether. They are not aphrodisiacs — they enable a response to arousal that's already there.

Don't get steered into testosterone therapy without confirmed low morning blood levels and actual symptoms. The marketing implies that "low T" is what's wrong with you; the data says only about two percent of men forty to seventy-nine meet honest criteria Wu et al. 2010. If your testosterone genuinely is low on two morning samples and you have the symptom pattern, replacement is a reasonable conversation — over a year, men over sixty-five on testosterone gel showed modest improvement in sexual desire and activity, with no benefit on general vitality versus placebo Snyder et al. 2016. If your level is borderline and you're carrying abdominal weight, sleeping poorly, drinking heavily, or depressed: fix those first. Most of the time the testosterone comes back up on its own Bhasin et al. 2018.

If you are a woman

The single most underused treatment in the whole entry is local vaginal estrogen. A pea-sized cream twice a week, or a small tablet, or a flexible ring left in for three months at a time. The amount that gets into the bloodstream is essentially zero. In four to twelve weeks it rebuilds vaginal tissue, ends dryness and painful sex, and meaningfully cuts the rate of recurrent urinary infections Lethaby et al. 2016. Its safety profile is so different from the systemic hormone therapy you've heard frightening things about that most breast cancer survivors can use it after a conversation with their oncologist. Fewer than one in ten women with these symptoms currently get it. This is the easiest big win on the page.

For hot flashes, night sweats, and sleep fragmentation that is hurting daytime function — systemic menopausal hormone therapy is back on the table for symptomatic women under sixty or within ten years of their last period. The Women's Health Initiative result that scared a generation off hormones has been substantially reframed: at eighteen-year follow-up there was no significant increase in all-cause mortality, and the subgroup starting therapy in their fifties had numerically lower mortality, not higher Manson et al. 2017. The North American Menopause Society's 2022 statement endorses the benefit-to-risk balance as favorable for symptomatic women in that window NAMS 2022. Transdermal estradiol (through-the-skin patch or gel) carries lower clot risk than the oral pill; if your uterus is intact, micronized progesterone is the modern progestin.

Pelvic floor physical therapy resolves a meaningful share of the painful sex, urinary leakage, and avoidance-driven loss of desire that older clinical lore treated as inevitable Dumoulin et al. 2018. A few sessions with a pelvic floor PT outperforms most of what you can Google.

Lifestyle, for both of you

The same things that bend cardiovascular risk bend sexual function. Aerobic exercise on most days, resistance training a couple of times a week, abdominal weight loss, smoking cessation, blood pressure control. Esposito's trial restored erectile function in roughly a third of obese men over two years with diet plus exercise alone Esposito et al. 2004. This is not consolation-prize advice — it is the same intervention that prevents the heart attack the bedroom trouble was warning you about.

If you are dating again

Condoms with new partners. Not for pregnancy — for the fastest-rising sexually-transmitted-infection demographic in the United States, which is now adults over fifty-five. Chlamydia, gonorrhea, and syphilis rates in this age group have risen roughly three to five times since 2010 CDC 2023. Why now: erection pills enable continued partnered sex; widowhood and divorce in your fifties and sixties expose people who haven't used condoms in decades to new partners; postmenopausal vaginal thinning makes transmission more efficient per encounter. Get tested when you change partners. Ask your clinician to add the standard infection panel to your annual blood work if you are dating — most of them will not offer it unprompted.

Things you've probably been told that aren't true

"Low desire in later life is just normal aging." Half of sexually active older adults report a bothersome problem; only between a fifth and two-fifths have raised it with their doctor Lindau et al. 2007. The gap between how common it is and how rarely it gets treated is the issue.

"Erection trouble is a sex problem." It is a blood-vessel problem that happens to show up sexually first. The same lining damage that has narrowed your penile arteries is working on your coronary and carotid arteries on the same schedule Vlachopoulos et al. 2013. Treat it that way.

"Hormone therapy causes breast cancer and heart attacks." The Women's Health Initiative headline that grounded that fear has been substantially walked back. For symptomatic women under sixty or within ten years of menopause, the long-term mortality data is reassuring and the symptom benefit is large Manson et al. 2017, NAMS 2022.

"Vaginal dryness is a comfort issue, not a medical one." Without treatment it is progressive — the tissue keeps thinning, sex keeps getting more painful, recurrent urinary infections become routine, and avoidance becomes permanent. Local vaginal estrogen is high-efficacy, low-risk, and underprescribed Lethaby et al. 2016.

"Testosterone will get an aging man's edge back." That is the marketing position, not the trial position. The data shows modest sexual desire improvement in confirmed-deficient symptomatic men over a year — and the confirmed-deficient symptomatic population is roughly two percent of men in the relevant age range, not the much larger group the clinics target Snyder et al. 2016, Wu et al. 2010.

"Older adults don't need to worry about sexually transmitted infections." Surveillance data is the direct contradiction — the rates are rising fastest in your demographic, not the teenagers' CDC 2023.

If you keep treating this as just aging

Fifty-five. The trouble in the bedroom has been there for two years, slowly. You haven't named it out loud, including to your partner. You shrug it off as the thing that happens. Your partner stops initiating. You stop initiating. The sex tapers to nothing over about a year, then it tapers to nothing at all. Nobody says it out loud.

What you don't know is that what started two years ago in the bedroom is going to arrive in your chest in about five years — the same artery-wall damage was working through the same body the whole time Vlachopoulos et al. 2013. The window in which a fifteen-minute conversation could have set off a cardiology referral, a statin, a walking habit, a different next decade — was the same two years you decided not to mention it. You don't get those years back.

Sixty-three. The hot flashes never quite stopped. Sex started hurting at fifty-two and you stopped wanting it. Your husband stopped asking. The closeness that used to live in the bedroom didn't relocate somewhere else — it just thinned. The friend at book club mentions she's been on a vaginal estrogen cream for two years and you almost cry, because you didn't know that existed and your gynecologist never asked.

Sixty-eight, dating again after a divorce. Nobody ever mentioned to you that syphilis rates in your demographic have nearly tripled in a decade CDC 2023. You catch it. The diagnosis takes months to land because nobody thinks to test for it in someone your age.

What changes if you raise it

First month after the appointment you finally took. The prescription is in the medicine cabinet. The first time you used it the relief was bigger than the function — the relief of finding out it wasn't, in fact, you. Your partner notices the change in your posture before they notice the change anywhere else. You are not, this morning, the person who has been quietly carrying a private problem for two years.

For the woman, six weeks into the local estrogen, the tissue has rebuilt. Sex does not hurt. You realize you'd been organizing your week — what you wore, whether you suggested a bath — around avoiding it without quite admitting that's what you were doing. That subroutine quietly turns off.

First year. The cholesterol panel taken at the workup came back borderline. You walk thirty minutes most days, drop the second nightly drink, eat closer to the Mediterranean pattern your cardiologist mentioned. The next panel is in the safe zone. You feel sharper — not because of any pill, but because of the walking, the sleep that came back, and the absence of a low-grade worry you didn't know was costing you bandwidth Esposito et al. 2004.

First decade. People in your cohort start having heart attacks. You don't have one. Your closest friendships and your partnership are the ones that survived the decade other relationships in your cohort didn't — the partnership in particular, because the bedroom never went quiet and the bedroom not going quiet kept you talking about everything else Holt-Lunstad et al. 2010. You are sixty-seven, you are still in your own skin, and you are not the version of yourself that quietly wrote off this part of being alive at fifty-five Davey Smith et al. 1997.

When not to act on your own

Almost everything in the protocol section is clinician-managed, not over-the-counter. The handful of drug combinations and conditions that change the calculus:

Erection pills (sildenafil, tadalafil, vardenafil) with any form of nitrate — nitroglycerin spray or tablets for chest pain, isosorbide, "poppers" — can drop blood pressure to lethal levels. Don't combine.
Unstable angina or a recent heart attack: defer ED treatment until a cardiologist has cleared you for sexual activity.
Testosterone replacement is not appropriate with untreated severe sleep apnea, an unusually high red-blood-cell count, or active prostate cancer; have a baseline prostate test before you start.
Systemic menopausal hormone therapy is not appropriate with a personal history of estrogen-sensitive breast cancer, a prior estrogen-related blood clot, active liver disease, or unexplained vaginal bleeding. Local vaginal estrogen has a much wider safety envelope — many of those patients can still use it after an oncology conversation.

Where this goes wrong in practice

The erection pill "didn't work" usually means inadequate dose, not enough actual sexual stimulation (these are not aphrodisiacs — they enable a response to arousal, they do not create one), or food timing (a heavy fatty meal blunts absorption of sildenafil). True non-response is the indication for a urology conversation about injections, vacuum devices, or implants — all of which work, and almost no one talks about.

The testosterone "didn't help" usually means the symptoms were not really about testosterone in the first place. Abdominal weight, untreated sleep apnea, heavy alcohol, depression were doing the work, and an injection on top did not fix any of them Wu et al. 2010.

The vaginal estrogen "didn't work" usually means giving it two weeks instead of eight. Or it means treating a painful-sex problem that also has a pelvic-floor muscle-tension component, or a psychological component from years of pain-anticipation, with estrogen alone. Three-pronged treatment (estrogen, pelvic floor PT, and sometimes a sex therapist) is what fixes the long-standing cases Dumoulin et al. 2018.

The menopausal hormone therapy "made me feel worse" sometimes traces to the progestin component; switching from synthetic progestins to micronized progesterone resolves a meaningful share of those cases NAMS 2022.

What lives next door

Adjacent territory worth following from here: sleep apnea (a quietly common cause of both low testosterone and erectile trouble in middle-aged men), pelvic floor physical therapy (relevant across continence, sexual function, and the slow consequences of childbirth decades after the kids), broader cardiovascular screening (the workup the erection trouble was telling you to do), and the specific topic of communication in long marriages, which is the substrate this entry quietly assumes.

Substance and claimed effects

Sexual health in aging is the trajectory of libido, arousal, orgasm, and partnered intimacy from roughly age 40 through the end of life, in both sexes, plus the medical and relational machinery that drives that trajectory. The substance is not "sex" as an activity — it is the integrated body system (vascular, hormonal, neural, urogenital) and relational scaffolding (partner availability, communication, mental health) that determines whether the activity is possible, satisfying, and safe. Claims attached: (i) treatable dysfunction is mistaken for inevitable decline; (ii) erectile dysfunction is a leading-edge marker of generalized atherosclerosis; (iii) menopause-related genitourinary atrophy is highly treatable with local estrogen; (iv) sexual frequency and intimate partnership are independently associated with reduced all-cause mortality; (v) sexually transmitted infections are rising in adults 55+ and routinely missed; (vi) common medications (SSRIs, beta-blockers, 5α-reductase inhibitors, opioids) cause iatrogenic sexual dysfunction that is reversible by drug change. The entry covers all six; meta scores reflect the substance holistically.

Evidence by addressing question

Mechanism

The dominant pathway in male aging is endothelial. Penile erection requires nitric-oxide–mediated relaxation of cavernosal smooth muscle and arterial inflow through cavernosal arteries 1–2 mm in diameter. Coronary arteries are 3–4 mm; internal carotids 5–7 mm. Atherosclerosis narrows the smallest vessels first, so endothelial dysfunction declares itself sexually 3–5 years before it declares itself with chest pain or stroke (Vlachopoulos et al. 2013; Thompson et al. 2005). Erectile dysfunction (ED) in a man under 70 is, mechanistically, a window into the same disease process that will kill him.

Hormonal pathways are secondary but real. Serum total testosterone falls roughly 1% per year after age 30–40 in longitudinal cohorts (Baltimore Longitudinal Study of Aging, Massachusetts Male Aging Study), with a secular decline on top of the age effect (Travison et al. 2007). Most low total testosterone in middle-aged men is, however, secondary — driven by obesity (SHBG suppression, aromatization), poor sleep, untreated sleep apnea, opioid use, or depression — and reverses when those drivers are addressed. True age-related primary hypogonadism with three sexual symptoms (low libido, ED, decreased morning erections) and total testosterone <11 nmol/L is found in only 2.1% of men 40–79 in the European Male Aging Study (Wu et al. 2010). The label "low-T" massively overshoots that prevalence.

In women, the menopausal transition (mean age 51 US/EU) collapses ovarian estradiol over 4–7 years. Two distinct clusters of consequences result. Vasomotor symptoms (hot flashes, night sweats) abate over 7–10 years in most women. Genitourinary syndrome of menopause (GSM) — vulvovaginal atrophy, thinning epithelium, loss of rugae, rising vaginal pH from acidic to neutral, reduced lubrication, dyspareunia, increased UTI risk — does not abate; it worsens with time without treatment (Portman & Gass 2014). The local estrogen pathway is the relevant target. Androgen decline in women is real but more gradual and clinically less load-bearing than the estrogen drop. Loss of pelvic floor tone (parity, atrophy, weight gain) reduces orgasmic intensity and contributes to incontinence that suppresses sexual interest.

Neuropsychiatric and pharmacologic pathways operate on top. Selective serotonin reuptake inhibitors produce sexual dysfunction (low desire, delayed orgasm, anorgasmia) in 58–73% of patients on prospective measurement — far higher than spontaneous patient report in the same trials (Montejo et al. 2001). Non-selective β-blockers (propranolol, older agents) raise ED rates; thiazides do as well. 5α-reductase inhibitors (finasteride, dutasteride) produce ED and low libido in ~3–15% of users, with a contested minority of persistent post-discontinuation cases. Chronic opioid use suppresses LH and testosterone. Each of these is iatrogenic and reversible by drug change.

Evidence — does treatment work, and does sexual activity itself carry health value

Sexual activity persists into late life and matters to the people having it. National Social Life, Health, and Aging Project (Lindau et al., NEJM 2007, N=3,005, US, ages 57–85): 73% of adults 57–64 reported sexual activity in the prior year, 53% at 65–74, 26% at 75–85. Among sexually active older adults, half reported at least one bothersome sexual problem; only 38% of men and 22% of women had discussed sex with a clinician since age 50 (Lindau et al. 2007). The pattern: activity continues, problems are common, problems go unraised.

ED predicts cardiovascular events. Vlachopoulos 2013 meta-analysis of 14 prospective cohorts (N≈92,000): ED associated with 44% higher CVD events (RR 1.44, 95% CI 1.27–1.63), 25% higher all-cause mortality (RR 1.25, 1.12–1.39), 19% higher stroke risk, 62% higher MI risk. The hazard is strongest in men 40–60 and attenuates above 70, consistent with ED-as-early-marker logic (Vlachopoulos et al. 2013). The Prostate Cancer Prevention Trial cohort: incident ED carried an HR of ~1.45 for CV events independent of conventional Framingham risk (Thompson et al. 2005).

Sildenafil and PDE5 inhibitors are robustly effective for ED. Pivotal RCT (Goldstein et al., NEJM 1998, N=861): improvement in successful intercourse from ~22% on placebo to ~69% on sildenafil 100 mg; effect across etiologies, including diabetes and post-prostatectomy (Goldstein et al. 1998). Tadalafil and vardenafil produce comparable response rates; tadalafil's 36-hour half-life and daily-low-dose option (2.5–5 mg) are clinically distinct features. Combining any PDE5 inhibitor with nitrates is an absolute contraindication — risk of life-threatening hypotension.

Testosterone therapy in symptomatic older men: modest sexual benefit, no proven CV harm at appropriate eligibility. Testosterone Trials (Snyder et al., NEJM 2016, N=790, men ≥65 with morning T <9.5 nmol/L plus symptoms): testosterone gel for 12 months improved sexual function (effect size ~0.5 SD on activity score), modest mood improvement, no benefit on vitality vs placebo. Testosterone increased trabecular bone strength and modestly improved anemia; cognition was unchanged (Snyder et al. 2016). TRAVERSE (2023) showed non-inferiority for major adverse cardiovascular events in hypogonadal men at high CV risk. Endocrine Society and AUA guidelines: confirm low total T on two morning samples, treat only if symptoms are present, target mid-normal range (Bhasin et al. 2018; Mulhall et al. 2018). Direct-to-consumer "low-T clinics" overshoot eligibility wildly.

Menopausal hormone therapy: the timing-hypothesis reframe. WHI reanalysis at 18-year follow-up (Manson et al., JAMA 2017, N≈27,000): no significant difference in all-cause mortality between MHT and placebo in either CEE-alone or CEE+progestin arms. Women initiating MHT at age 50–59 or within 10 years of menopause showed numerically lower all-cause mortality (HR ~0.69 in some subgroups), while initiation at 70+ showed numerically higher risk — the "timing hypothesis" (Manson et al. 2017). NAMS 2022 position statement: for symptomatic women under 60 or within 10 years of menopause, the benefit-risk balance of systemic MHT is favorable for vasomotor symptoms, bone protection, and quality of life (NAMS 2022). The post-2002 collapse in MHT prescribing (down ~70% in the US) is increasingly judged an overcorrection.

Local vaginal estrogen for GSM: high efficacy, minimal systemic risk. Cochrane review (Lethaby et al. 2016, 30 RCTs): low-dose vaginal estradiol or estriol tablets, creams, and rings consistently improve dyspareunia, vaginal dryness, urinary urgency, and recurrent UTI rate; systemic estradiol levels remain in the postmenopausal range; endometrial proliferation negligible at recommended doses (Lethaby et al. 2016). Unlike systemic MHT, local vaginal estrogen has essentially no thromboembolic or breast cancer signal at therapeutic doses (long debated; current NAMS and ACOG positions support use even in many breast cancer survivors after oncologist consultation). Underprescribed — a study in 2017 found <10% of postmenopausal women with GSM receive any treatment.

Lifestyle reverses much male sexual dysfunction. Esposito 2004 RCT in obese men with ED (N=110): Mediterranean diet + exercise vs control for 2 years restored normal erectile function in ~1 in 3 of intervention-arm men, with improvements in endothelial function markers (Esposito et al. 2004). Health Professionals Follow-up Study (Bacon et al., Ann Intern Med 2003, N≈31,000 men): physical activity, normal BMI, non-smoking, and moderate alcohol each independently predicted preserved sexual function over 14-year follow-up (Bacon et al. 2003).

Sexual frequency and mortality. Caerphilly cohort (Davey Smith et al., BMJ 1997, N=918 men, 10-year follow-up): age-adjusted mortality in men in the highest orgasm-frequency tertile was roughly half that of the lowest tertile (OR ~0.5 for all-cause mortality), with a stronger effect for fatal coronary events. The authors noted reverse causation as a candidate explanation but the effect persisted after adjustment for baseline health (Davey Smith et al. 1997). Mechanism plausibility: orgasm produces parasympathetic rebound, oxytocin release, transient lowering of blood pressure; sexual activity is light-to-moderate aerobic exercise; partnered relationships drive social-connection effects. The intimate-partnership signal is the more replicated one: Holt-Lunstad meta-analysis of 148 studies (N≈308,000): strong social relationships associated with ~50% higher odds of survival; effect comparable to smoking cessation, larger than obesity (Holt-Lunstad et al. 2010). Subsequent meta-analysis (2015) finds loneliness raises mortality ~26%, social isolation ~29%, living alone ~32%, all independent of baseline health (Holt-Lunstad et al. 2015).

STIs in older adults are rising. CDC STI Surveillance 2022: chlamydia, gonorrhea, and syphilis rates in adults 55+ have risen 3–5× since 2010, off a low absolute base. Syphilis especially: primary/secondary syphilis incidence in adults 55–64 nearly tripled 2012–2022 (CDC 2023). Drivers: PDE5 inhibitors enable continued partnered sex; widowhood and divorce at 50+ produce new partner exposure with no functioning condom culture (no pregnancy worry); dating apps lower partner-pool friction; postmenopausal vaginal atrophy (thinner epithelium, microabrasions) raises HIV/HSV transmission efficiency per exposure. Clinicians under-screen older patients; patients underreport sexual history.

Protocol — what actually works at the level of individual action

Modifiable cardiovascular risk first. Smoking cessation, blood pressure control to <130/80, fasting glucose normalization, abdominal adiposity reduction, weekly aerobic exercise (Esposito's RCT regimen ≈ 150 min/week + 60 min/week resistance), Mediterranean-style diet. The same actions that prevent MI prevent ED, and reverse some of it (Esposito et al. 2004).

Medication review. Β-blocker switch (carvedilol or nebivolol have lower sexual side-effect rates than atenolol/propranolol). SSRI switch to bupropion or mirtazapine where clinically appropriate. Finasteride risk discussion before initiating. Opioid taper where feasible.

PDE5 inhibitor first-line for ED (sildenafil 25–100 mg PRN, tadalafil 5 mg daily or 10–20 mg PRN). Absolute contraindication with nitrates; caution with α-blockers. AUA, EAU, and BSSM guidelines aligned (Hackett et al. 2018; Mulhall et al. 2018).

For women with GSM: low-dose vaginal estrogen tablet (10 µg estradiol twice weekly), cream, or ring; non-hormonal lubricants and moisturizers for symptomatic relief; ospemifene as a non-estrogen oral option. Topical lidocaine for entry dyspareunia. Pelvic floor physiotherapy for muscle tension dyspareunia and incontinence-driven avoidance (Dumoulin et al. 2018).

For symptomatic perimenopausal/postmenopausal women within 10 years of FMP and under 60: systemic MHT (transdermal estradiol preferred for lower VTE risk; micronized progesterone if uterus intact) discussed as standard care, not last resort (NAMS 2022).

For men with biochemically confirmed hypogonadism (T <264 ng/dL or <9.2 nmol/L on two morning fasted samples) plus sexual symptoms: testosterone replacement after counseling regarding fertility suppression, polycythemia monitoring, and PSA surveillance; transdermal gel or weekly/biweekly intramuscular formulations standard (Bhasin et al. 2018).

STI screening at any age with new partners. Condoms with new partners, regardless of pregnancy status. PrEP for HIV consideration in higher-risk patterns.

Contraindications

PDE5 inhibitors with nitrates: lethal hypotension. PDE5 inhibitors with α-blockers: relative caution, dose stagger. Recent MI or unstable angina: defer ED treatment until stable on Princeton Consensus risk-stratification grounds. Testosterone in untreated severe sleep apnea, polycythemia (Hct >54%), active prostate cancer (relative): worsen with androgens. Systemic MHT in women with personal history of estrogen-sensitive breast cancer, prior VTE on estrogen, active liver disease, or unexplained vaginal bleeding. Local vaginal estrogen has a much wider safety envelope; in many breast cancer survivors it remains an option after oncology consultation.

Misconceptions

"Low sex drive in older age is normal and doesn't need treatment" — half of sexually active older adults report bothersome dysfunction (Lindau et al. 2007); treatable causes are common. "Erectile dysfunction is a sexual problem" — it is the small-vessel manifestation of a systemic vascular condition, and the right reaction is a CV workup (Vlachopoulos et al. 2013; Thompson et al. 2005). "Testosterone therapy will revitalize an aging man" — the symptom envelope is narrower than direct-to-consumer marketing implies; trials show modest sexual benefit only, and the eligibility population is small (Snyder et al. 2016; Wu et al. 2010). "Hormone therapy causes breast cancer and heart disease" — the WHI generalization to all women has been substantially walked back by the timing hypothesis (Manson et al. 2017; NAMS 2022). "Vaginal dryness is a comfort issue, not a medical one" — GSM is progressive, and topical estrogen is high-efficacy, low-risk (Lethaby et al. 2016; Portman & Gass 2014). "Older adults don't need to worry about STIs" — CDC 2022 data contradicts directly (CDC 2023).

Audience and population variability

The entry's audience is adults 40+, both sexes. Differences in pathway and clinical handling are deep enough that male and female sub-sections are warranted; gender-scoped guidance is necessary, not optional. Within sex, key modifiers: presence of cardiovascular risk (statistically dominant on ED severity in men); history of pelvic surgery, prostatectomy, hysterectomy (mechanical sources of dysfunction); diabetes (neuropathy as well as vasculopathy); cancer survivors (chemotherapy gonadotoxicity, surgical effects); SSRIs and other neuro-active medications; sleep apnea; chronic opioid use. Partner availability — widowhood disproportionately affects women in their 70s and 80s — is a major determinant of sexual activity that no medical intervention addresses.

Stakes (substance absence)

The downside of ignoring sexual health in midlife is twofold. Direct: bothersome dysfunction continues unrelieved when it is treatable, intimacy in long partnerships erodes, libido-loss-driven relationship distress is widespread (Lindau: half of sexually active older adults report a problem; only ~20–40% have raised it with a clinician). Indirect: a man whose ED is unevaluated has an undiagnosed cardiovascular risk profile sitting 3–5 years in front of a possible MI (Vlachopoulos et al. 2013). A postmenopausal woman whose GSM goes untreated develops progressive atrophy, recurrent UTIs, dyspareunia-driven avoidance that often becomes permanent (Portman & Gass 2014). Iatrogenic sexual side effects (SSRIs, β-blockers) that could have been resolved with a drug switch are accepted as aging. STI exposure goes unscreened; late syphilis diagnoses are now appearing in geriatric clinics.

Payoff (substance adoption)

Within months of treatment: ED responsive to PDE5 inhibitors in ~70% of users; GSM symptoms resolve in 4–12 weeks of local estrogen (Goldstein et al. 1998; Lethaby et al. 2016). Within a year of lifestyle change: meaningful restoration of erectile function in a third of obese men (Esposito et al. 2004). Over a decade: maintained intimate partnership and sexual activity associate with lower all-cause mortality (Davey Smith et al. 1997; Holt-Lunstad et al. 2010). Workup of ED detects subclinical CV disease early enough to act on it — the same window in which lifestyle, statins, and BP control bend the trajectory.

Failure modes

PDE5 inhibitor "doesn't work" most commonly means inadequate dose, insufficient sexual stimulation (these are not aphrodisiacs), or first-pass timing error (sildenafil with high-fat meal). True non-response (advanced diabetic vasculopathy, post-prostatectomy nerve damage) is the indication for intracavernosal injection, vacuum device, or penile prosthesis. Testosterone "didn't help" usually reflects misdiagnosis — symptoms attributable to obesity, depression, or sleep apnea, not to androgen deficiency. Vaginal estrogen "didn't work" usually means inadequate duration (4–12 weeks needed) or single-modality treatment of multi-factor dyspareunia (pelvic floor and psychological dimensions ignored). MHT "made me feel worse" sometimes reflects progestin component intolerance; switching from synthetic progestins to micronized progesterone resolves a meaningful fraction.

Credibility range

Optimist case

Sexual function is one of the most modifiable dimensions of aging. The vascular axis in men yields to the same interventions that prevent cardiovascular events; the hormonal axis in women yields to local estrogen with a safety profile better than most commonly used drugs; iatrogenic dysfunction reverses by changing the offending drug. Partnered intimacy carries a population-scale mortality signal comparable to smoking cessation (Holt-Lunstad et al. 2010). The reason adults in their 60s and 70s are not sexually flourishing is, in most cases, untreated medical issues plus clinician silence, not biology. Acting on the substance early (40s, 50s) compounds across the next 30 years: better cardiovascular endpoints, lower depression incidence, stronger partnerships, preserved continence.

Skeptic case

Mortality findings on sexual frequency are observational with strong reverse-causation candidates; healthier men have more sex, and the residual signal after adjustment may be over-attributed. The Caerphilly cohort is one mid-sized study from a single Welsh population; replication is thinner than the headline statistic suggests (Davey Smith et al. 1997). Testosterone replacement carries a long shadow: trials are short (≤3 years), polycythemia is real, and PSA monitoring requirements are not trivial; the case for treating asymptomatic low-T does not exist. Direct-to-consumer testosterone clinics overshoot indications and may be doing net harm at population level. MHT remains contested in detail: the WHI-vs-timing-hypothesis debate is real, and individual cancer-risk discussions remain non-trivial. PDE5 inhibitors enable sexual activity but do not restore endothelial function; the cardiovascular workup the ED should have prompted often does not happen. STI prevention in older adults is a behavioral problem more than a medical one, and behavioral interventions are weak.

Author's call

The substance is high-evidence on its main components (ED ↔ CVD, GSM ↔ local estrogen, PDE5i efficacy, lifestyle reversibility) and the practical advice is well-defined. Controversy concentrates in a few specific places: routine testosterone replacement (skeptical lean, narrow indications honored), systemic MHT for asymptomatic primary prevention (skeptical), systemic MHT for symptomatic women under 60 (favorable per NAMS), the strength of the sexual-frequency mortality effect (suggestive, not definitive). The article will write the high-confidence material plainly and flag the contested material as contested. Evidence score: 4. Controversy score: 2 (real but localized).

Stakeholder and incentive map

PDE5 inhibitor manufacturers — sildenafil/tadalafil generic since 2013/2018; lower marketing incentive than peak years but residual.
"Low-T" / men's clinic industry — strong commercial incentive to expand testosterone indications; routinely overshoots Endocrine Society/AUA eligibility. The catalogue should not amplify this.
Compounded hormone industry — pushes "bioidentical" custom formulations on questionable safety/efficacy grounds vs FDA-approved transdermal estradiol + micronized progesterone, which are themselves bioidentical.
Menopause specialists (NAMS, IMS, BMS) — pushing back on post-WHI under-treatment; their position is the current best synthesis (NAMS 2022).
Primary care — often the first stop and frequently undertrained on this material; consequence is that GSM goes unmentioned, ED is treated as "a sex problem" not a CV signal.
Geriatric medicine — increasingly recognizes the STI rise but screening practices lag.
Cultural / community — strong cultural assumption that older adults are asexual; primary failure mode is patient non-disclosure plus clinician non-inquiry.

Population variability

Men: ED prevalence rises from ~5% complete at 40 to ~15% at 70 (Feldman MMAS) with a long tail of partial dysfunction; cardiovascular comorbidity drives most of the variance (Feldman et al. 1994). True age-related hypogonadism is rare (~2% in EMAS) (Wu et al. 2010).

Women: GSM prevalence 27–84% postmenopausal depending on diagnostic threshold; vasomotor symptoms in ~75%; sexual dysfunction prevalence ~40% but bothersome dysfunction ~12% (Shifren et al. 2008 cohort). Surgical menopause (oophorectomy before natural age) produces a more abrupt and severe symptom profile. Premature ovarian insufficiency (~1% of women under 40) is a distinct entity requiring earlier intervention.

Both sexes: diabetes accelerates the timeline of dysfunction by ~10 years. Cancer survivorship (especially prostate cancer, breast cancer on aromatase inhibitors, pelvic radiotherapy) produces distinct dysfunction profiles requiring specialist support. Single, divorced, or widowed older adults — especially women — face partner-availability constraints that no medical intervention resolves; community and social-connection interventions matter independently.

Knowledge gaps

(i) Causal direction of the sexual-frequency / mortality association remains incompletely settled; only an RCT could close it and one cannot be done. (ii) Long-term safety of testosterone replacement beyond 3 years is not RCT-supported; TRAVERSE addressed short-term CV safety but not 10-year endpoints. (iii) Optimal timing of MHT initiation in perimenopause (vs strict postmenopausal start) lacks RCT power. (iv) STI behavioral-intervention efficacy in older adults is essentially unstudied — most prevention research targets adolescents and young adults. (v) Female sexual dysfunction pharmacotherapy: flibanserin and bremelanotide have small effect sizes and significant tolerability issues; the field lacks a sildenafil-equivalent for women. (vi) Post-finasteride syndrome: contested entity; case series exist, RCT evidence does not.

Scope versus brief. The brief named libido, arousal, function, the vascular/hormonal/relational drivers, STI risk in older adults, and links to cardiovascular health, mood, intimacy, and quality of life. The article covers all six end-to-end. Both sexes are kept in one entry rather than split into male sexual aging and female sexual aging — the shared material (cardiovascular connection, lifestyle reversibility, iatrogenic drug effects, STI re-risk on partner change, partnership-mortality signal) is larger than the divergence; the sex-specific protocol material is scoped with audience blocks.

Separate-entry candidates surfaced during writing. Several substances inside this entry are deep enough to deserve their own page once the catalogue grows: menopausal hormone therapy (the WHI / timing-hypothesis debate alone warrants a dedicated entry), erectile dysfunction as a standalone cardiovascular signal, testosterone replacement therapy (controversy is sharp enough that nuance is owed), local vaginal estrogen for genitourinary syndrome of menopause, STIs in older adults, and post-prostatectomy and cancer-survivor sexuality. When those exist, this entry should link to them rather than carry the depth.

Future-link candidates. Sleep apnea (a hidden driver of low testosterone and ED in middle-aged men), broad cardiovascular screening, pelvic floor physical therapy, and a future entry on partnered communication / intimacy in long marriages — all of these were referenced in the out-of-scope closer and should be wired up if they land.

Rating calls worth flagging.

Longevity = 3. Borderline 3 vs 4. The Caerphilly halving of mortality is striking but is one mid-sized study with reverse-causation candidates; the partnership / social-connection signal (Holt-Lunstad et al. 2010) is more replicated; the ED-as-CV-early-marker effect bends a real curve but is partly already captured under evidence. 3 reads honest; 4 would have implied a dominant mortality intervention on the order of the catalogue's top longevity entries.
Energy = 2 and focus = 1. Both are downstream effects (via mood, sleep, and removed worry) rather than direct mechanisms of the substance. Kept non-zero because the downstream chain is well-evidenced, but scored low to avoid over-claiming. The payoff section's "feel sharper… absence of a low-grade worry you didn't know was costing you bandwidth" is the article's coverage of those scores.
Beauty (cumulative) = 0. Considered a 1 on partnered-intimacy and reduced-stress grounds and rejected — evidence is too thin to call this an effect of the substance.
Controversy = 2. Localized to three things: routine testosterone replacement indications, the WHI-vs-timing-hypothesis debate for systemic menopausal hormone therapy, and the magnitude of the sexual-frequency / mortality association. Everything else is broadly consensus. The article calls each contested area out as contested rather than presenting one position as settled.

Excluded by design.

Post-prostatectomy and post-pelvic-radiation sexuality. Mentioned in passing under ED treatment options but not given depth — warrants its own entry with surgical-recovery and oncology context.
Female sexual desire pharmacotherapy (flibanserin, bremelanotide). Small effect sizes, real tolerability issues, contested ROI; not strong enough to include as a recommendation, only flagged briefly in the research dossier.
Post-finasteride syndrome. Contested entity; case series exist, RCT evidence does not. Flagged in research credibility range but not in article — the asymmetry of giving column-inches to a contested syndrome relative to its evidence base would have misled.
Lubricants, sex toys, vibrators for arousal-disorder treatment. Real-world useful, but mostly trivial — kept out for length.
Couples therapy and sex therapy as standalone interventions. Mentioned in failure-modes as the third leg of treatment for long-standing painful sex; not given its own section.

Voice and dream-tier note. Overall score lands at roughly 42 by the spec's weighted formula — above the dream-narrative floor of 40. The dek and tagline carry the projection (the bedroom-not-going-quiet hook), the opening paragraph leans bold in the same register, and the payoff section is a felt-experience forecast rather than a study summary. The chosen lever is aspiration tilted with relief: the catalogue audience here is mostly people quietly accepting a thing as inevitable, and the strongest emotional charge is the relief of finding out it isn't.